Despite of the relatively few numbers of samples subject to Arraystar analysis, the subsequent clinical validation of 96 pairs of tissues solidly confirmed the upregulation of LBX2-AS1 in ccRCC. This evidence concerns the gene LBX2 and nonpapillary renal cell carcinoma.